Negative / Null Result ReportOpen accessMedicine· cited by 76

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

Toby M. Maher; Ulrich Costabel; Marilyn K. Glassberg; Yasuhiro Kondoh; Takashi Ogura; Mary Beth Scholand; David Kardatzke; Monet Howard · 2020 · European Respiratory Journal

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF). Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%–100% predicted and diffusing capacity for carbon monoxide of 25%–90% predicted and who were treatment-naïve (cohort A) or receiving pirfenidone (2403 mg·day −1 ; cohort B) were randomised 1:1 to receive lebrikizumab 250 mg or placebo subcutaneously every 4 weeks. The

Abstract by Toby M. Maher; Ulrich Costabel; Marilyn K. Glassberg; Yasuhiro Kondoh; Takashi Ogura; Mary Beth Scholand; David Kardatzke; Monet Howard, European Respiratory Journal (2020) — licensed CC BY 4.0.

Read the full paper (open access)